Evidence Level
Strong
2 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

Vitamin E is a group of eight fat-soluble compounds — four tocopherols and four tocotrienols — with alpha-tocopherol being the most biologically active form in humans. It serves as a primary lipid-soluble antioxidant, protecting cell membranes from oxidative damage.

Studied Dose 15 mg/day (RDA); therapeutic studies use 400–1,000 IU/day
Active Compound d-alpha-Tocopherol (natural) / dl-alpha-Tocopherol (synthetic) — mixed tocopherols preferred

Antioxidant protection

Alpha-tocopherol is the primary fat-soluble antioxidant in cell membranes, donating hydrogen atoms to lipid peroxyl radicals and terminating chain reactions that would otherwise destroy membrane integrity.

Immune modulation

Enhances T-cell proliferation and natural killer cell activity. Studies show supplementation improves immune response in elderly individuals, who typically exhibit lower vitamin E status.

Cardiovascular support

Reduces oxidation of LDL cholesterol, a key step in atherosclerotic plaque formation. Mixed tocopherols show more consistent effects than alpha-tocopherol alone.

Skin health

Protects skin cell membranes from UV-induced oxidative damage. Commonly used topically and orally to support wound healing and reduce photoaging markers.

1

Lipid peroxidation termination

Alpha-tocopherol donates a hydrogen atom to lipid peroxyl radicals (LOO•), converting them to lipid hydroperoxides and generating a tocopheroxyl radical, which is then regenerated by vitamin C. This interrupts the chain reaction of lipid peroxidation.

2

Gene expression regulation

Tocopherols modulate expression of genes involved in inflammation (NF-κB pathway), cellular adhesion, and immune cell differentiation independent of their antioxidant activity.

3

Platelet aggregation inhibition

Vitamin E inhibits platelet aggregation by reducing thromboxane synthesis and protein kinase C activity, contributing to its cardiovascular protective effects.

1
HOPE Trial: Vitamin E Supplementation and Cardiovascular Events
PubMed

RCT of 400 IU/day vitamin E vs. placebo in 9,541 high-risk cardiovascular patients over 4.5 years.

9,541 adults with CVD or diabetes. 4.5-year follow-up.

No significant reduction in cardiovascular events or cancer. No benefit on primary endpoints. Highlighted limitations of alpha-tocopherol alone for CVD prevention.

2
Vitamin E and Immune Function in Elderly Adults
PubMed

RCT of vitamin E supplementation (200 mg/day) vs. placebo in 88 adults over age 65 for 4 months.

88 elderly adults. 4-month intervention.

Significant improvement in delayed-type hypersensitivity response, antibody titers, and T-cell proliferation. Supports use in elderly populations.

Common Potential side effects

GI upset, nausea, and diarrhea at doses above 1,000 mg/day
Fatigue and weakness with chronic high-dose supplementation
Increased bleeding risk at very high doses (>1,000 IU/day)

Important Drug interactions

Anticoagulants (warfarin, aspirin) — high-dose vitamin E enhances anticoagulant effect; monitor INR
Statins and niacin — antioxidant vitamins may blunt HDL-raising effects when combined
Chemotherapy agents — may reduce efficacy; consult oncologist before use